Skip to content

Clinical Evaluation of the Zynex Monitoring System, Model CM-1600

Clinical Evaluation of the Zynex Monitoring System, Model CM-1600

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05740644
Enrollment
20
Registered
2023-02-23
Start date
2023-02-13
Completion date
2023-02-22
Last updated
2024-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fluid Loss

Brief summary

This is a prospective, single-arm, non-randomized, non-controlled single-center study for the evaluation of the Zynex CM-1600 in 20 healthy adults undergoing a manual blood loss of up to 500mL followed by an infusion of 1 liter of normal saline.

Interventions

DEVICECM-1600

Healthy subjects undergoing a manual blood loss of up to 500mL followed by an infusion of 1 liter of normal saline will be connected to the CM-1600 device.

Sponsors

Zynex Monitoring Solutions
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Participant must have the ability to understand the parameters of participation and provide written informed consent * Male or female of any race * Participant is adult 18 or older * Participant must be willing and able to comply with study procedures and duration * In the Principal Investigator's medical judgment, the participant is suitable for a blood draw of up to 500mL * Participant must weigh at least 110 pounds

Exclusion criteria

* Any upper extremity amputation * Females who are pregnant, who are trying to get pregnant, or have a urine test positive for pregnancy on the day of the study * Participant has a heart condition that may interfere with the Zynex CM-1600 (e.g., pacemakers, defibrillator, irregular heartbeat, dextrocardia, etc.) * Participant has been diagnosed with chronic fatigue syndrome (also known as chronic fatigue, immune dysfunction syndrome, or myalgic encephalomyelitis) * Participant requires equipment and/or devices that may interfere with the Zynex CM-1600 (e.g., life-sustaining equipment, other monitoring devices, insulin pumps, or other implanted devices) * Participant is taking coumadin (warfarin), heparin, or other prescription blood thinners for 7 or more days prior to blood draw * Participant donated blood within 8 weeks prior to the study blood draw * Participant has high or low blood pressure on the day of blood draw (high blood pressure is defined as systolic \> 180 mmHg or diastolic \> 100 mmHg; low blood pressure is defined as systolic \< 100 mmHg or diastolic \< 60 mmHg) * Participant has symptoms of an active infection or a temperature ≥ 100 °F * Female with hemoglobin levels of less than 12.1g/dL or male with hemoglobin levels of less than 13.8g/dL * Participants with self-reported heart or cardiovascular conditions such as: * History of cardiovascular surgery * History of chest pain (angina) * Heart rhythms other than a normal sinus rhythm or respiratory sinus arrhythmia * History heart attack/myocardial infarction * Peripheral arterial disease * Carotid artery disease * Unexplained shortness of breath * Congestive heart failure (CHF) * History of stroke/transient ischemic attack * Myocardial ischemia * Cardiomyopathy * Dextrocardia * Participants with clotting disorders such as: * Hemophilia * History of blood clots * History of bleeding problems * Bruises easily * Self-reported health conditions as identified in the Health Assessment Form including: * Diabetes * Uncontrolled thyroid disease * Kidney disease / chronic renal impairment * History of seizures (except childhood febrile seizures) * Epilepsy * History of unexplained syncope * Recent history of frequent migraine headache within the last 2 months * Recent head injury within the last 2 months * History of cancer, with or without chemotherapy within the last 2 months * Other known health conditions deemed unsuitable for participation by the PI when considered upon disclosure on health assessment form

Design outcomes

Primary

MeasureTime frameDescription
CM-1600 Ability to Detect Minor Blood LossDuration of Recovery Period following blood draw (10 minutes)The objective of this study is to determine if manual blood loss of up to 500mL of blood can be identified using the non-invasive Zynex CM-1600. This will be measured by determining the percent change in Relative Index (RI) before and after the Blood Draw. The RI is an investigational value which utilizes proprietary algorithms to combine the changes of multiple measured parameters (utilizing a weighted summation of percent change values) which are indicative of relative changes in fluid volume in adult patients into a single value. The RI is a unitless value with no set minimum or maximum, where 100 is a patient's baseline. Based on the nature of the RI itself, a direct interpretation of a positive or negative outcome cannot be derived from the absolute value, instead it could be used to monitor trending of a patient's parameters relative to their baseline.
CM-1600 Ability to Detect Saline ReinfusionRecovery period following saline reinfusion (10 minutes)The objective of this study is to determine if a saline reinfusion of 1000mL of normal saline can be identified using the non-invasive Zynex CM-1600. This will be measured by determining the percent change in Relative Index (RI) before and after the Saline Reinfusion. The RI is an investigational value which utilizes proprietary algorithms to combine the changes of multiple measured parameters (utilizing a weighted summation of percent change values) which are indicative of relative changes in fluid volume in adult patients into a single value. The RI is a unitless value with no set minimum or maximum, where 100 is a patient's baseline. Based on the nature of the RI itself, a direct interpretation of a positive or negative outcome cannot be derived from the absolute value, instead it could be used to monitor trending of a patient's parameters relative to their baseline.

Countries

United States

Participant flow

Participants by arm

ArmCount
Blood Loss and Saline Infusion
CM-1600: Healthy subjects undergoing a manual blood loss of up to 500mL followed by an infusion of 1 liter of normal saline will be connected to the CM-1600 device.
20
Total20

Baseline characteristics

CharacteristicBlood Loss and Saline Infusion
Age, Continuous39.2 years
STANDARD_DEVIATION 12.2
Race and Ethnicity Not Collected— Participants
Region of Enrollment
United States
20 participants
Sex: Female, Male
Female
10 Participants
Sex: Female, Male
Male
10 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 20
other
Total, other adverse events
0 / 20
serious
Total, serious adverse events
0 / 20

Outcome results

Primary

CM-1600 Ability to Detect Minor Blood Loss

The objective of this study is to determine if manual blood loss of up to 500mL of blood can be identified using the non-invasive Zynex CM-1600. This will be measured by determining the percent change in Relative Index (RI) before and after the Blood Draw. The RI is an investigational value which utilizes proprietary algorithms to combine the changes of multiple measured parameters (utilizing a weighted summation of percent change values) which are indicative of relative changes in fluid volume in adult patients into a single value. The RI is a unitless value with no set minimum or maximum, where 100 is a patient's baseline. Based on the nature of the RI itself, a direct interpretation of a positive or negative outcome cannot be derived from the absolute value, instead it could be used to monitor trending of a patient's parameters relative to their baseline.

Time frame: Duration of Recovery Period following blood draw (10 minutes)

ArmMeasureValue (MEAN)Dispersion
Blood LossCM-1600 Ability to Detect Minor Blood Loss8.0 Percent change in RIStandard Deviation 23.6
Primary

CM-1600 Ability to Detect Saline Reinfusion

The objective of this study is to determine if a saline reinfusion of 1000mL of normal saline can be identified using the non-invasive Zynex CM-1600. This will be measured by determining the percent change in Relative Index (RI) before and after the Saline Reinfusion. The RI is an investigational value which utilizes proprietary algorithms to combine the changes of multiple measured parameters (utilizing a weighted summation of percent change values) which are indicative of relative changes in fluid volume in adult patients into a single value. The RI is a unitless value with no set minimum or maximum, where 100 is a patient's baseline. Based on the nature of the RI itself, a direct interpretation of a positive or negative outcome cannot be derived from the absolute value, instead it could be used to monitor trending of a patient's parameters relative to their baseline.

Time frame: Recovery period following saline reinfusion (10 minutes)

ArmMeasureValue (MEAN)Dispersion
Blood LossCM-1600 Ability to Detect Saline Reinfusion10.2 Percent changeStandard Deviation 38.2

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026